- Home
- AMRN vs SCPH Comparison
AMRN vs SCPH Comparison
Compare AMRN & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- SCPH
- Stock Information
- Founded
- AMRN 1989
- SCPH 2013
- Country
- AMRN Ireland
- SCPH United States
- Employees
- AMRN N/A
- SCPH N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- SCPH Health Care
- Exchange
- AMRN Nasdaq
- SCPH Nasdaq
- Market Cap
- AMRN 317.1M
- SCPH 299.0M
- IPO Year
- AMRN 1993
- SCPH 2017
- Fundamental
- Price
- AMRN $14.65
- SCPH $5.64
- Analyst Decision
- AMRN Strong Sell
- SCPH Buy
- Analyst Count
- AMRN 1
- SCPH 3
- Target Price
- AMRN $12.00
- SCPH $12.00
- AVG Volume (30 Days)
- AMRN 49.5K
- SCPH 2.4M
- Earning Date
- AMRN 10-29-2025
- SCPH 11-12-2025
- Dividend Yield
- AMRN N/A
- SCPH N/A
- EPS Growth
- AMRN N/A
- SCPH N/A
- EPS
- AMRN N/A
- SCPH N/A
- Revenue
- AMRN $219,361,000.00
- SCPH $49,969,000.00
- Revenue This Year
- AMRN N/A
- SCPH $104.30
- Revenue Next Year
- AMRN N/A
- SCPH $76.06
- P/E Ratio
- AMRN N/A
- SCPH N/A
- Revenue Growth
- AMRN N/A
- SCPH 107.79
- 52 Week Low
- AMRN $7.08
- SCPH $1.94
- 52 Week High
- AMRN $17.49
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- AMRN 41.02
- SCPH 64.33
- Support Level
- AMRN $14.54
- SCPH $4.33
- Resistance Level
- AMRN $15.46
- SCPH $5.62
- Average True Range (ATR)
- AMRN 0.44
- SCPH 0.04
- MACD
- AMRN -0.06
- SCPH -0.01
- Stochastic Oscillator
- AMRN 9.24
- SCPH 93.40
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.